The FDA approved Anzupgo for the treatment of moderate to severe chronic hand eczema in adults who do not adequately respond ...

The U.S. Food and Drug Administration (FDA) has signed off on the first-ever cream specifically approved for treating chronic ...

Adult patients with moderate to severe hand eczema with previous treatment failure or in whom topical corticosteroids are ...

The first therapy specifically indicated for chronic hand eczema (CHE) has passed muster at the FDA.

Ballerup, Denmark Saturday, July 26, 2025, 15:00 Hrs [IST] ...

Danish dermatology specialist Leo Pharma has scored an FDA approval that makes its JAK inhibitor cream Anzupgo (del | Despite chronic hand eczema affecting 1 in 10 people worldwide, there was no ...

LEO Pharma’s Anzupgo (delgocitinib) cream has been approved by the US Food and Drug Administration (FDA) to treat adults with ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The topical JAK inhibitor is the first treatment approved specifically for adults with moderate-to-severe chronic hand eczema.

[2] Transcriptomic profiling of chronic hand eczema skin reveals shared immune pathways and molecular drivers across subtypes. Journal of Allergy and Clinical Immunology (2025).

Hand eczema manifests as inflammation, dryness, and sometimes fissuring that compromise the skin’s barrier function, leading to discomfort and impaired manual dexterity.